Released Aug 8, 2023, before the open
10-Q filed Aug 8, 2023, 39 days after period end · 0001576885-23-000050
Q2 2023 · 10-Q
Revenue—
Net Income-$11.61M-$11.61M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.28-$0.28 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$13,478,000N/M
Operating Cash Flowderived-$11,670,000N/M
Free Cash Flowderived-$11,670,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$11.61M | -$10.15M | -$61.36M | -$2.04M |
| EPS Diluted | -$0.28 | -$0.25 | -$141.93 | -$4.86 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR